The countdown is on with Argenica’s phase II trial results of lead drug ARG-007 in acute ischaemic stroke patients forecast ... Read More The post Clock ticking as Argenica nears phase II stroke trial ...

The uncertainty surrounds who will be able to get updated vaccines in coming months – shots created to protect against more ...

Precision medicine revolutionizes cancer care, empowering patients with personalized insights and targeted therapies while ...

Cuts to the NIH hurting the scientific community at large, but cuts to the NIH hurt our families and friends in our home ...

There are mad inventions, such as weight-loss drugs or the contraceptive Pill, that come out of the blue and change the world ...

Key Points Surrozen reported GAAP EPS of $2.55 for Q2 2025, exceeding expectations by $3.66 per share (GAAP) due to significant one-time and non-cash gains. Surrozen recorded $1.0 million in research ...

Knowable Magazine reports that studying dogs' cancers offers insights into human cancer, due to similar pathways and faster ...

Over the past two centuries, vaccines have been critical for preventing infectious diseases. The World Health Organization ...

Less than one-quarter of next-in-class cancer drugs demonstrated a survival benefit over existing in-class agents in head-to-head trials.

GAAP net loss per share was $(11.29) for Q2 2025, missing the consensus GAAP EPS estimate of $(4.62) by a wide margin, mainly due to a $17.0 million up-front license fee. NextCure advanced both its ...

Curreen Capital breaks down Fortrea’s struggles and turnaround potential. Learn why this CRO stock might rebound and what it means for long-term investors.

Pirtobrutinib had a nominally superior overall response rate compared to ibrutinib in certain patients with chronic ...